Lysosomal destroyers (siromecin) and tyrosine kinase inhibitors (lapatinib) can increase the delivery of iron to cells by extracellular transferrin and inhibit the discharge of iron ions dominated by iron transporters, thereby increasing intracellular iron ion levels, promoting ferroptosis in breast cancer cells, and becoming a new drug for the treatment of breast cancer 113. Here, TF is linked to breast carcinoma.